Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Inclisiran, a small interfering RNA that targets PCSK9 mRNA, was given as a single injection at baseline or in two doses at baseline and 90 days. At 180 days, LDL cholesterol was significantly lowered among persons at high cardiovascular risk who had elevated levels at baseline. Low-density lipoprot...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 376; číslo 15; s. 1430 - 1440
Hlavní autoři: Ray, Kausik K, Landmesser, Ulf, Leiter, Lawrence A, Kallend, David, Dufour, Robert, Karakas, Mahir, Hall, Tim, Troquay, Roland P.T, Turner, Traci, Visseren, Frank L.J, Wijngaard, Peter, Wright, R. Scott, Kastelein, John J.P
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 13.04.2017
Témata:
Aged
Anticholesteremic Agents - administration & dosage
Anticholesteremic Agents - adverse effects
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - prevention & control
Cholesterol
Cholesterol, LDL - blood
Dose-Response Relationship, Drug
Double-Blind Method
Female
Gene expression
Humans
Hypercholesterolemia - drug therapy
Injection
Injections, Subcutaneous
Kexin
Low density lipoprotein
Male
Middle Aged
mRNA
Proprotein Convertase 9 - antagonists & inhibitors
Proprotein Convertase 9 - blood
Proprotein convertases
Risk Factors
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - adverse effects
siRNA
Statins
Subtilisin
Transaminases - blood
ISSN:0028-4793, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Inclisiran, a small interfering RNA that targets PCSK9 mRNA, was given as a single injection at baseline or in two doses at baseline and 90 days. At 180 days, LDL cholesterol was significantly lowered among persons at high cardiovascular risk who had elevated levels at baseline. Low-density lipoprotein (LDL) cholesterol is a causal factor in atherosclerotic cardiovascular disease. Statins have been shown to reduce LDL cholesterol levels and cardiovascular events in large outcome trials, findings that have made them the therapeutic cornerstone of clinical practice. 1 Despite the proven efficacy of statins, there is considerable variability in individual responses to these drugs. 2 Furthermore, some observational data suggest that as many as half of persons who begin statin therapy discontinue it within a year. 3 Moreover, among patients receiving statin therapy who are at high risk for cardiovascular disease and who have persistent elevation of LDL cholesterol levels, the . . .
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1615758